



Approved for use through 03/31/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/595,932-Conf. #9163	
			Filing Date	May 19, 2006	
			First Named Inventor	Mladen Mercep	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	03818/0204413-US0

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/K.C.	AA*	US-6,511,976	01-28-2003	Andres-Gil et al.	
/K.C.	AB*	US-4,145,434	03-20-1979	VAN DER Burg et al.	
/K.C.	AC*	US-3,711,489	01-16-1973	Lombardino	
/K.C.	AD*	US-4,198,421	04-15-1980	Cherkofsky et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code ² -Number-Kind Code ² (if known)					
/K.C.	BA	WO-99/19317		04-22-1999	Janssen Pharmaceutica N.V.		
/K.C.	BB	WO-97/38991		10-23-1997	Janssen Pharmaceutica N.V.		
/K.C.	BC	EP-0063525		10-27-1982	Centre National de la Recherche Scientifique		
/K.C.	BD	WO-96/14320		05-17-1996	Janssen Pharmaceutica N.V.		
/K.C.	BE	WO-96/14321		05-17-1996	Janssen Pharmaceutica N.V.		
/K.C.	BF	CA-967,573		05-13-1975	Pfizer Inc.		
/K.C.	BG	WO-01/87890		11-22-2001	Piiva d.d.		
/K.C.	BH	WO-03/097648		11-27-2003	PLIVA - ISTRAZIVACKI INSTITUT D.O.O.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). ‡See Kinds Codes of USPTO Patent Documents at uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ‡Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				†
/K.C.	CA	Wermuth et al: "Molecular Variations Based on Isosteric Replacements", Practice of Medicinal Chemistry, XX, XX, 1996 PAGES 203-237, XPOO2190259				
/K.C.	CB	F.Bymaster, et al. " New Approaches to developing antidepressants by enhancing monoaminergic neurotransmission" Expert Opinion Investig. Drugs 2003, 12, 531-543				
/K.C.	CC	U. Spampinato, et al. " Role of Striatal Serotonin 2A and Serotonin 2C Receptor Subtypes in the Control of In Vivo Dopamine Outflow in the Rat Striatum" J. Neurochemistry 2000, vol. 74, pgs. 693-701				
/K.C.	CD	F.P. Monnet, et al. "N-Methyl-D-aspartate-induced neuronal activation is selectively modulated by α receptors", European Journal of Pharmacology, 1990, vol. 179., pgs. 441-445.				
/K.C.	CE	Ciaghorn, J. et al, "Recent developments in antidepressant agents" Progress in Drug Research Clinic Inc., 1996, vol.46, pgs.243-262.				
/K.C.	CF	Sperling, W. et al " New Tetracyclic Antidepressants" Drugs Today , 1997, vol. 33, No. 2, pgs. 95-102.				

Examiner Signature	Date Considered
--------------------	-----------------



Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/595,932-Conf. #9163
		Filing Date	May 19, 2006
		First Named Inventor	Mladen Mercep
		Art Unit	N/A
		Examiner Name	Not Yet Assigned
Sheet	2	of	2
		Attorney Docket Number	03818/0204413-US0

/K.C./	CG	J. Ignacio Andres et al. " R107500.A new 5-HT 2A/2C Antagonist with Potential Anxiolytic Profile" Drugs Fut. 2002, vol. 27, Suppl. A: C41	
/K.C./	CH	Jose M. Cid, et al., " Synthesis of 2-aminomethyl-3, 3a, 8, 12,"Drugs Fut. 2002, vol 27, Suppl. A: P182	
/K.C./	CI	Berge S. M. et al. "Pharmaceutical Salts," Journal of Pharmaceutical Sciences., 1977; Vol. 66: pages 1-20	
/K.C./	CJ	Wolf, W.A. et al. "The Serotonin 5-HT 2C Receptor is a Prominent Serotonin Receptor in Basal Ganglia: Evidence from Functional Studies on Serotonin-Mediated Phosphoinositide Hydrolysis" Journal of Neurochemistry, 1997, vol. 69: pgs. 1449	
/K.C./	CK	Milan, M.J. et al., "S18126 ((2-4-2,3-dihydrobenzo[1,4] dioxin-8-yl)piperazin-1-yl)methyl), A Potent, Selective and Competitive Antagonist at Dopamine D4 Receptors: An in vitro and in Vivo Comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyridol(2,3b)pyridine) and Raclopride, 1998, Journal of Pharmacology and Experimental Therapeutics, vol. 287: No. 1 pages 167-186.	
/K.C./	CL	Saucier, C. et al. "Identification of an Endogenous 5-Hydroxytryptamine 2A Receptor in NIH-3T3 Cells: Agonist-Induced Down-Regulation Involves Decreases in Receptor RNA and Number" Journal of Neurochemistry, 1997, vol 68, No. 1, pages 1998 - 2011	
/K.C./	CM	T.F. Meert, et al. " Psychopharmacology of Rilanserin: Comparison with Chlordiazepoxide ", Drug Development Research , 1989, vol. 18, pgs.119-144	
/K.C./	CN	Thomson W. et al. , " Juvenile Idiopathic Arthritis Genetics - What's new? What's next? Arthritis Research, 2002, vol 4 and 5: pgs 302-306	
/K.C./	CO	PCT International Search Report for International No. PCT/HR2004/000051, dated April 19, 2005	
/K.C./	CP	Niemegeers, C.J.E., et al, "Interaction of Drugs with Apomorphine, Tryptamine and Norepinephrine. A New "in vivo" Approach: the ATN-Test in Rats", Arch. Int. Pharmacodyn. Vol. 227, pages 238-253 (1977).	
/K.C./	CQ	Porsolt R.D. et al. " Behavioural Despair in Mice: A Primary Screening Test for Antidepressants " Arch. Int. Pharmacodyn. Vol. 229, pages 327-336 (1977)	
/K.C./	CR	Bonhaus D.W. , et al , " The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5HT2C receptors " British Journal of Pharmacology, (1995), Vol, 115: pages 622-628	
/K.C./	CS	Smrz, R. et al., "Neurotropic and psychotropic agents. CIII. 2(8)-Chloro-10(11)- (dimethylaminoalkyl)di benzo b,f]thiepines as potential CNS agents; synthesis and pharmacological screening" (1977)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Kendra Carter/	Date Considered	07/01/2009
-----------------------	-----------------	--------------------	------------